Key Insights

Highlights

Success Rate

90% trial completion (above average)

Research Maturity

57 completed trials (51% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

5.4%

6 terminated out of 112 trials

Success Rate

90.5%

+4.0% vs benchmark

Late-Stage Pipeline

3%

3 trials in Phase 3/4

Results Transparency

12%

7 of 57 completed with results

Key Signals

7 with results90% success

Data Visualizations

Phase Distribution

71Total
Not Applicable (29)
Early P 1 (5)
P 1 (16)
P 2 (18)
P 3 (2)
P 4 (1)

Trial Status

Completed57
Recruiting19
Unknown16
Active Not Recruiting11
Terminated6
Withdrawn2

Trial Success Rate

90.5%

Benchmark: 86.5%

Based on 57 completed trials

Clinical Trials (112)

Showing 20 of 20 trials
NCT04993768Phase 2CompletedPrimary

A Phase 2a Study of TPN-101 in Patients With Progressive Supranuclear Palsy (PSP)

NCT03225144Recruiting

Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia

NCT05222386Not ApplicableActive Not Recruiting

Community Outreach for Palliative Engagement -- Parkinson Disease

NCT05819658Phase 2CompletedPrimary

GV1001 Subcutaneous(SC) for the Treatment of Progressive Supranuclear Palsy (PSP)

NCT03872102Recruiting

Facilitating Diagnostics and Prognostics of Parkinsonian Syndromes Using Neuroimaging

NCT06588673Not ApplicableActive Not RecruitingPrimary

Art Therapy in Progressive Supranuclear Palsy

NCT05956834Active Not Recruiting

A Multi-Modal Remote Monitoring Platform for Frontotemporal Lobar Degeneration (FTLD) Syndromes

NCT05913687Active Not Recruiting

Automated Imaging Differentiation of Parkinsonism

NCT06647641Recruiting

The CurePSP Genetics Program

NCT07291687Not ApplicableRecruitingPrimary

tDCS as Treatment for Motor Function

NCT02605785Not ApplicableRecruitingPrimary

A Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear Palsy

NCT06235775Phase 2CompletedPrimary

Administration of GV1001 for the Treatment of Progressive Supranuclear Palsy Who Completed Study GV1001-PSP-CL2-011

NCT06529744Recruiting

Improving Prognostic Confidence in Neurodegenerative Diseases Causing Dementia Using Peripheral Biomarkers and Integrative Modeling

NCT05459753Not ApplicableActive Not Recruiting

Cholinergic Mechanisms of Attentional-motor Integration and Gait Dysfunction in Parkinson Disease (UDALL)

NCT06355531Phase 2Active Not RecruitingPrimary

A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP)

NCT02236832Not ApplicableCompleted

Study of the Neural Basis of Analogical Reasoning

NCT05889260Completed

Speech Accessibility Project

NCT04658199Phase 1Active Not RecruitingPrimary

A Study to Test the Safety and Tolerability of Long-term UCB0107 Administration in Study Participants With Progressive Supranuclear Palsy

NCT04518059Completed

Misfolded Proteins in the Skin of People With Parkinson's Disease and Other Parkinsonism

NCT02994719Recruiting

Gait Analysis in Neurological Disease

Scroll to load more

Research Network

Activity Timeline